| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 05/19/2005 | WO2004016726A3 Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms |
| 05/19/2005 | WO2003049678A3 Mitotic kinesin inhibitors |
| 05/19/2005 | WO2003009815A3 Compositions and methods for modulating blood-brain barrier transport |
| 05/19/2005 | WO2002069893A3 Treatment of neurological disease |
| 05/19/2005 | US20050107578 Medical devices and applications of polyhydroxyalkanoate polymers |
| 05/19/2005 | US20050107465 Composition for treating inflammatory bowel disease |
| 05/19/2005 | US20050107450 administering Peroxisome Proliferator Activated Receptors (PPAR-gamma) activators according to a dosage schedule which comprises a cycle of less than daily administration |
| 05/19/2005 | US20050107441 screening for drugs that alter glucose production by modulating gene expression and/or activity of the nuclear receptor short heterodimer partners, then using the drugs as hypoglycemic or hyperglycemic agents; antidiabetic agents; metabolic disorders |
| 05/19/2005 | US20050107425 in mammals comprising administering alpha-7-nicotinic acetylcholine receptors (alpha-7-nAChR) agonists, and psychostimulants and/or monoamine reuptake inhibitors |
| 05/19/2005 | US20050107417 Medicaments for inhalation comprising a novel anticholinergic and a betamimetic |
| 05/19/2005 | US20050107416 17-hydroxy 4-aza androstan -3-ones as androgen receptor modulators |
| 05/19/2005 | US20050107411 Method for treating circadian rhythm disruptions |
| 05/19/2005 | US20050107405 administering cyclic guanosine monophosphate phosphodiestarase (cGMP PDE5) inhibitors such as sildenafil salts, as analgesics or antispasmodic agents |
| 05/19/2005 | US20050107404 Mitotic kinesin inhibitors |
| 05/19/2005 | US20050107403 Carbonylpyridine or carbonylpyrimindine compounds containing another nitrogen containing ring; useful in the treatment of inflammatory, metabolic or malignant conditions |
| 05/19/2005 | US20050107394 Novel use of selective pde5 inhibitors |
| 05/19/2005 | US20050107392 treatment of disease such as diabetes, obesity, hyperlipidemia, and atherosclerotic disease; e.g. ethyl (5-methoxy-2,3-dihydro-1H-inden-1-ylidene)ethanoate |
| 05/19/2005 | US20050107386 Methods of treating diseases and disorders by targeting multiple kinases |
| 05/19/2005 | US20050107384 to inhibit proliferative conditions, such as cancer and psoriasis; detecting or identifying a HDAC in a biological sample comprising detecting or measuring the formation of a complex between a labelled compound as defined in claim (I) and a HDAC |
| 05/19/2005 | US20050107380 Administering substance P receptor antagonist selected from the group consisting of L 742694, L 758298, and LY 303241, a non-toxic magnesium compound and a pharmaceutically acceptable vehicle |
| 05/19/2005 | US20050107356 synergistic effect; CB1 receptor antagonist is an azetidine compound of given formula such as 1-[bis(4-chlorophenyl)methyl]-3-[(3,5-difluorophenyl)(methylsulfonyl)methylene]-azetidine), and the dopaminergic agent is ropinirole for example |
| 05/19/2005 | US20050107354 Preventive or therapeutic agent for kidney disease |
| 05/19/2005 | US20050107353 Methods of treating lower urinary tract disorders using losigamone |
| 05/19/2005 | US20050107351 provides for the reduction or elimination of administered ethinyl estradiol in the first phase without a reduction in contraceptive efficacy or an increase in undesired side effects |
| 05/19/2005 | US20050107330 Drug mixture contains a sympathomimetic selected from the group consisting oxymetazoline, xylometazoline, tramazoline, tetryzoline and naphazoline, and glycosaminoglycan of hyaluronic acid; synergistic effect; vasoconstrictor action, detumescent action on the nose mucous membrane |
| 05/19/2005 | US20050107322 Compositions for inducing immune responses |
| 05/19/2005 | US20050107309 Lowering elevated post-prandial blood glucose levels by increasing incretin half-life comprising administering inhibitor of Dipeptidyl Peptidase (DP IV) or enzymes having DP-IV-like activity; insulinotropic effects are enhanced |
| 05/19/2005 | US20050107293 Protein modification and maintenance polypeptides (PMOD) for use as diagnostic and therapeutic tools in treatment of prevention of gastrointestinal, cardiovascular, autoimmune/inflammatory, cell proliferative, developmental, epithelial, neurological, and reproductive disorders |
| 05/19/2005 | US20050107291 Compositions and methods for treating or preventing diseases of body passageways |
| 05/19/2005 | US20050107287 Administering cisplatin; drug delivery; reduced dosage to prevent release into systemic circulation; platinum containing compound entrapped in salt crystals; andone or more lipids |
| 05/19/2005 | US20050107277 Polyalkylene polymer compounds and uses thereof |
| 05/19/2005 | US20050107256 Carbohydrate binding domain containing fusion proteins for delivery of therapeutic and other agents, and compositions containing them |
| 05/19/2005 | US20050106679 Leptin proteins |
| 05/19/2005 | US20050106675 Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof |
| 05/19/2005 | US20050106670 Isolated human G-protein coupled receptors that are members of the aminergic subfamily, nucleic acid molecules encoding human GPCR proteins, and uses thereof |
| 05/19/2005 | US20050106654 Animal model lacking histone deacetylase (HDAC) for use as diagnostic tool in detection, diagnosis and prevention of cardiac hypertrophy |
| 05/19/2005 | US20050106638 Immunoglobulin for use in diagnosis, prevention and treatment of fibrosis and scarring; antiscarring agents |
| 05/19/2005 | US20050106620 Novel ovarian tumor antigen (OVR107) for use in diagnosis, prognosis, classification and imaging of cell proliferative disorders |
| 05/19/2005 | US20050106614 Reagents and methods useful for detecting diseases of the prostate |
| 05/19/2005 | US20050106586 Detection of neurodegenerative diseases |
| 05/19/2005 | US20050106581 Phosphodiesterase polypeptides for use in identifying modulators for prevention and treatment of inflammatory disease |
| 05/19/2005 | US20050106267 Zeolite molecular sieves for the removal of toxins |
| 05/19/2005 | US20050106266 docosahexaenoic acid and a calcium compound (carbonate, hydroxide,sulfate) |
| 05/19/2005 | US20050106262 colon tumour, gastric tumour, mammary tumour, ovarian tumour, prostate tumour, and renal tumour |
| 05/19/2005 | US20050106259 GRAS two acid low pH compound consisting of citric and hydrochloric or phosphoric acids |
| 05/19/2005 | US20050106231 Liposome-entrapped topoisomerase inhibitors |
| 05/19/2005 | US20050106230 Drug-enhanced adhesion prevention |
| 05/19/2005 | US20050106220 Administering gamma-aminobutyric acid receptor antagonist |
| 05/19/2005 | US20050106217 Adjust fatty acid oxidation; stimulating carnitine palmitoyl transferase |
| 05/19/2005 | US20050106212 Using electrochemical mixture of metal compound and bioactive material; contacting substrate |
| 05/19/2005 | US20050106153 mixture of immunoadjuvant in neoplasm; applying stresses to destroy neoplastic tissue; administering immunomoderator ; in situ generation of autologous vaccine |
| 05/19/2005 | US20050106148 Method of treating blood disorders |
| 05/19/2005 | US20050106142 Rheumatic arthritis; hepatitis c virus; autoimmune diseases ; nterfering with forming or binding of such; autoantigen |
| 05/19/2005 | US20050106135 Compositions, kits and treating methods for alteration cell-cell adhesion, transport, or permeation properties of tissues |
| 05/19/2005 | US20050106131 Photoprotective orally administrable composition for skin |
| 05/19/2005 | US20050106099 Fusion proteins |
| 05/19/2005 | CA2545157A1 Disinfecting composition and methods of making and using same |
| 05/19/2005 | CA2544924A1 Methods and compositions for treating mcp-1 related pathologies |
| 05/19/2005 | CA2544863A1 Selective erbb2 inhibitor/anti-erbb antibody combinations in the treatment of cancer |
| 05/19/2005 | CA2543610A1 Transdermal analgesic systems having reduced abuse potential |
| 05/19/2005 | CA2543602A1 Triazole compounds and uses related thereto |
| 05/19/2005 | CA2543508A1 Controlled release analgesic suspensions |
| 05/19/2005 | CA2542509A1 Salts of pharmacologically active compounds |
| 05/19/2005 | CA2538218A1 Compositions of botanical extracts for cancer therapy |
| 05/18/2005 | EP1530969A1 Combination chemotherapy |
| 05/18/2005 | EP1530724A2 Diagnosis and prevention of cancer cell invasion |
| 05/18/2005 | EP1530632A2 Growth factor which acts through erb b-4 rtk |
| 05/18/2005 | EP1530586A2 Isolated human secreted proteins, nucleic acid molecules encoding human secreted proteins, and uses thereof |
| 05/18/2005 | EP1530494A1 A pharmaceutical preparation containing palladium complex compounds and the uses thereof for treating cancer and autoimmune disease |
| 05/18/2005 | EP1530476A1 Use of reboxetine for the treatment of hot flashes |
| 05/18/2005 | EP1530475A2 Pharmaceutical compositions comprising an allosteric carboxylic inhibitor of matrix metalloproteinase-13 and a selective inhibitor of cyclooxygenase-2 |
| 05/18/2005 | EP1530471A1 Inhalation medicaments containing a novel anticholinesterase drug in conjunction with corticosteroids and betamimetic drugs |
| 05/18/2005 | EP1530469A2 Transdermal dosage form comprising an active agent and a salt and free-base form of an antagonist |
| 05/18/2005 | EP1530466A2 Use of lck inhibitor for treatment of immunologic diseases |
| 05/18/2005 | EP1326502B1 Method for preparing a mixture that can be granulated and carnitine-magnesium hydroxycitrate |
| 05/18/2005 | EP1233787B8 Product inhibiting transduction of g heterotrimeric protein signals combined with another anti-cancer agent for therapeutic use in cancer treatment |
| 05/18/2005 | EP1224195B1 C-aryl glucoside sglt2 inhibitors |
| 05/18/2005 | EP1145011B1 Compositions and methods for the diagnosis and treatment of tumor |
| 05/18/2005 | EP1066402B1 Methods of screening agents for activity using teleosts |
| 05/18/2005 | EP1007058B1 Use of (n)-substituted-1,5-dideoxy-1,5-imino-d-glucitol compounds in combination therapy for treating hepatitis virus infections |
| 05/18/2005 | EP0830138B1 Use of fibroblast growth factor analogues to stimulate bone growth |
| 05/18/2005 | CN1617884A Beta-amyloid binding factors and inhibitors thereof |
| 05/18/2005 | CN1617871A Purine derivatives as purinergic receptor antagonists |
| 05/18/2005 | CN1617865A Phenylalkynes |
| 05/18/2005 | CN1617849A Hiv整合酶抑制剂 Hiv integrase inhibitors |
| 05/18/2005 | CN1617755A Fpt inhibitor and use of other anti-tumor agent in combination in preparing anticancer drug |
| 05/18/2005 | CN1617744A Combined therapy against tumors comprising substituted acryloyl distamycin derivatives and protein kinase (serine/threonine kinase) inhibitors |
| 05/18/2005 | CN1617743A New pharmaceutical combinations for nos inhibitors |
| 05/18/2005 | CN1617742A Methods for treating cancer by using tumor-derived dentrical cell inhibitory factor antagonist in combination with toll-like receptor agonist |
| 05/18/2005 | CN1617739A Methods and compositions for treating lesions of the respiratory epithelium |
| 05/18/2005 | CN1617731A Use of DSRNAs in strategic therapeutic intervention of highly active antiretroviral therapy |
| 05/18/2005 | CN1617729A Use of benzothiazepines having activity as inhibitors of ileal bile acid transport for reducing cholesterololemia |
| 05/18/2005 | CN1617728A Antidiabetic formulation and method |
| 05/18/2005 | CN1617727A Selective dopamin D3 receptor agonists for the treatment of sexual dysfunction |
| 05/18/2005 | CN1617725A Tyrosyl derivatives and their use as P2X7 receptor modulators |
| 05/18/2005 | CN1617724A Neurotransmitter balance chemotherapy |
| 05/18/2005 | CN1617721A Substituted 2-thio-3, 5-dicyano-4-phenyl-6-aminopyridines and use thereof |
| 05/18/2005 | CN1617719A Combination comprising a P-GP inhibitor and an anti-epileptic drug |
| 05/18/2005 | CN1617718A N-aryl-N'-arylcycloalkyl-urea derivatives as MCH antagonists for the treatment of obesity |
| 05/18/2005 | CN1617715A Treating muscle wasting with selective androgen receptor modulators |